Sort:
Date
Filter:
All

174 result(s) found

Johnson & Johnson wins FDA AdCom backing for Carvykti label expansion https://seekingalpha.com/news/4080088-jj-wins-fda-adcom-carvykti-label-expansion?source=feed_sector_healthcare Mar 15, 2024 - FDA advisors unanimously voted to expand labeling for Carvykti, a CAR-T therapy developed by J&J (JNJ) and Legend Biotech (LEGN), for multiple myeloma. Read more here.
The Smartest Dividend Stocks to Buy With $400 Right Now https://www.fool.com/investing/2024/03/15/the-smartest-dividend-stocks-to-buy-with-400-right/?source=iedfolrf0000001 Mar 15, 2024 - It's time to reward yourself with companies that treat their shareholders with steady and growing payouts.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446 Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Esta es la combinación de SEO que necesitas para vencer al algoritmo de Google https://www.entrepreneur.com/es/marketing/esta-es-la-combinacion-de-seo-que-necesitas-para-vencer-al/471202 Mar 14, 2024 - Para obtener una presencia en línea que brinde resultados y altas clasificaciones a largo plazo, crea una estrategia que se centre en combinar las mejores prácticas de SEO y las directrices de E-A-T (Experiencia, Autoridad, Confianza) — aquí te decimos cómo.
JPST: Good Short-Term Income Fund, But Not A Buy At These Levels https://seekingalpha.com/article/4678163-jpst-good-short-term-income-fund-but-not-a-buy-at-these-levels?source=feed_tag_etf_portfolio_strategy Mar 14, 2024 - JPMorgan Ultra-Short Income ETF is quite similar to T-bills, with slightly higher risk, and slightly higher returns. Read more on JPST ETF here.
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology https://www.zacks.com/stock/news/2240226/allogene-allo-inks-deal-with-arbor-bio-for-crispr-technology?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240226 Mar 13, 2024 - Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.
Here's the SEO Combination You Need to Win Google's Algorithm https://www.entrepreneur.com/growing-a-business/heres-the-seo-combination-you-need-to-win-googles/469814 Mar 12, 2024 - For an online presence that delivers results and high rankings long term, create a strategy that focuses on combining SEO best practices and E-E-A-T guidelines — here's how.
What Makes T. Rowe (TROW) a New Strong Buy Stock https://www.zacks.com/stock/news/2237533/what-makes-t-rowe-trow-a-new-strong-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2237533 Mar 07, 2024 - T. Rowe (TROW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
W&T (WTI) Reports Q4 Earnings: What Key Metrics Have to Say https://www.zacks.com/stock/news/2236364/w-t-wti-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2236364 Mar 05, 2024 - While the top- and bottom-line numbers for W&T (WTI) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Earnings Estimates Rising for T. Rowe (TROW): Will It Gain? https://www.zacks.com/stock/news/2236197/earnings-estimates-rising-for-t-rowe-trow-will-it-gain?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-2236197 Mar 05, 2024 - T. Rowe (TROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Pages: 1234567891011...18

<<<Page 6>